Skip Nav Destination
Issues
1 May 2012
-
Cover Image
Cover Image
Jag1, a Notch ligand, enhances proliferation of adrenocortical carcinoma (ACC) cells. Pictured are ACC cells expressing dsRedII (Red) cocultured with ACC cells coexpressing GFP (GFP) and Jag1 shRNA. With cells plated at a ratio of 90% to 10% (red and green cells, respectively), Jag1 knockdown was found to diminish ACC cell proliferation in a non–cell-autonomous manner consistent with a Notch receptor–dependent effect of Jag1 on adrenal cancer growth. For details, see the article by Simon and colleagues on page 2452 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR New Strategies
Molecular Pathways
Review
Human Cancer Biology
Detection and Characterization of a Novel Subset of CD8+CD57+ T Cells in Metastatic Melanoma with an Incompletely Differentiated Phenotype
Richard C. Wu; Shujuan Liu; Jessica A. Chacon; Sheng Wu; Yufeng Li; Pariya Sukhumalchandra; James L. Murray; Jeffrey J. Molldrem; Patrick Hwu; Hanspeter Pircher; Gregory Lizée; Laszlo G. Radvanyi
Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients
Elliot L. Servais; Christos Colovos; Luis Rodriguez; Adam J. Bograd; Jun-ichi Nitadori; Camelia Sima; Valerie W. Rusch; Michel Sadelain; Prasad S. Adusumilli
IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma
Daniel Gorovets; Kasthuri Kannan; Ronglai Shen; Edward R. Kastenhuber; Nasrin Islamdoust; Carl Campos; Elena Pentsova; Adriana Heguy; Suresh C. Jhanwar; Ingo K. Mellinghoff; Timothy A. Chan; Jason T. Huse
Cancer Therapy: Preclinical
The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms
Kim H.T. Paraiso; H. Eirik Haarberg; Elizabeth Wood; Vito W. Rebecca; Y. Ann Chen; Yun Xiang; Antoni Ribas; Roger S. Lo; Jeffrey S. Weber; Vernon K. Sondak; Jobin K. John; Amod A. Sarnaik; John M. Koomen; Keiran S.M. Smalley
Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
Giorgia Migliardi; Francesco Sassi; Davide Torti; Francesco Galimi; Eugenia R. Zanella; Michela Buscarino; Dario Ribero; Andrea Muratore; Paolo Massucco; Alberto Pisacane; Mauro Risio; Lorenzo Capussotti; Silvia Marsoni; Federica Di Nicolantonio; Alberto Bardelli; Paolo M. Comoglio; Livio Trusolino; Andrea Bertotti
Pharmacokinetics and Antitumor Efficacy of XMT-1001, a Novel, Polymeric Topoisomerase I Inhibitor, in Mice Bearing HT-29 Human Colon Carcinoma Xenografts
Mark D. Walsh; Suzan K. Hanna; Jeremy Sen; Sumit Rawal; Carolina B. Cabral; Alex V. Yurkovetskiy; Robert J. Fram; Timothy B. Lowinger; William C. Zamboni
Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
Celina García-García; Yasir H. Ibrahim; Violeta Serra; Maria Teresa Calvo; Marta Guzmán; Judit Grueso; Claudia Aura; José Pérez; Katti Jessen; Yi Liu; Christian Rommel; Josep Tabernero; José Baselga; Maurizio Scaltriti
Imaging, Diagnosis, Prognosis
Proximal Fluid Proteome Profiling of Mouse Colon Tumors Reveals Biomarkers for Early Diagnosis of Human Colorectal Cancer
Remond J.A. Fijneman; Meike de Wit; Maral Pourghiasian; Sander R. Piersma; Thang V. Pham; Marc O. Warmoes; Mehrdad Lavaei; Chloe Piso; Fiona Smit; Pien M. Delis-van Diemen; Sietze T. van Turenhout; Jochim S. Terhaar sive Droste; Chris J.J. Mulder; Marinus A. Blankenstein; Els C. Robanus-Maandag; Ron Smits; Riccardo Fodde; Victor W.M. van Hinsbergh; Gerrit A. Meijer; Connie R. Jimenez
Cancer Therapy: Clinical
Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors
Aung Naing; Patricia LoRusso; Siqing Fu; David S. Hong; Pete Anderson; Robert S. Benjamin; Joseph Ludwig; Helen X. Chen; Laurence A. Doyle; Razelle Kurzrock
The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial
Jason J. Luke; David R. D'Adamo; Mark A. Dickson; Mary Louise Keohan; Richard D. Carvajal; Robert G. Maki; Elisa de Stanchina; Elgilda Musi; Samuel Singer; Gary K. Schwartz
A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
Klaus Mross; Annette Frost; Simone Steinbild; Susanne Hedbom; Martin Büchert; Ulrike Fasol; Clemens Unger; Jörn Krätzschmar; Roland Heinig; Oliver Boix; Olaf Christensen
Phase I Trial of Intraperitoneal Pemetrexed, Cisplatin, and Paclitaxel in Optimally Debulked Ovarian Cancer
Setsuko K. Chambers; H-H. Sherry Chow; Mike F. Janicek; Janiel M. Cragun; Kenneth D. Hatch; Haiyan Cui; Cynthia Laughren; Mary C. Clouser; Janice L. Cohen; Heather M. Wright; Nisreen Abu Shahin; David S. Alberts
Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
Steven G. DuBois; Louis Chesler; Susan Groshen; Randall Hawkins; Fariba Goodarzian; Hiroyuki Shimada; Greg Yanik; Michael Tagen; Clinton Stewart; Yael P. Mosse; John M. Maris; Denice Tsao-Wei; Araz Marachelian; Judith G. Villablanca; Katherine K. Matthay
A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
Udai Banerji; Leni van Doorn; Dionysis Papadatos-Pastos; Rebecca Kristeleit; Phillip Debnam; Matthew Tall; Adam Stewart; Florence Raynaud; Michelle Dawn Garrett; Martin Toal; Leon Hooftman; Johann Sebastian De Bono; Jaap Verweij; Ferry ALM Eskens
Predictive Biomarkers and Personalized Medicine
A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors
Marcus Schmidt; Birte Hellwig; Seddik Hammad; Amnah Othman; Miriam Lohr; Zonglin Chen; Daniel Boehm; Susanne Gebhard; Ilka Petry; Antje Lebrecht; Cristina Cadenas; Rosemarie Marchan; Joanna D. Stewart; Christine Solbach; Lars Holmberg; Karolina Edlund; Hanna Göransson Kultima; Achim Rody; Anders Berglund; Mats Lambe; Anders Isaksson; Johan Botling; Thomas Karn; Volkmar Müller; Aslihan Gerhold-Ay; Christina Cotarelo; Martin Sebastian; Ralf Kronenwett; Hans Bojar; Hans-Anton Lehr; Ugur Sahin; Heinz Koelbl; Mathias Gehrmann; Patrick Micke; Jörg Rahnenführer; Jan G. Hengstler
Common PIK3CA Mutants and a Novel 3′ UTR Mutation Are Associated with Increased Sensitivity to Saracatinib
John J. Arcaroli; Kevin S. Quackenbush; Rebecca W. Powell; Todd M. Pitts; Anna Spreafico; Marileila Varella-Garcia; Lynne Bemis; Aik Choon Tan; Jaclyn M. Reinemann; Basel M. Touban; Arvind Dasari; S. Gail Eckhardt; Wells A. Messersmith
Letters to the Editor
Corrections
Advertisement
